Protagonist Therapeutics Quarterly Income Statement
NASDAQ: PTGXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Protagonist Therapeutics revenue and earnings
In the quarter ended Jun 30, 2026, Protagonist Therapeutics generated $213.5 million in revenue, up 3749.2% from the same quarter a year earlier. Net income was $162.8 million, for a net margin of 76.3% versus a median of -596.8% in the prior 5 quarters. Operating margin was 74.4%.
Diluted earnings per share came in at $2.29.
Summary generated from market data by MetaCap's automated system. Methodology
Protagonist Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 213.47M | 56.37M | 7.44M | 4.71M | 5.55M | 28.32M | 170.64M | 4.67M | 4.17M | 254.95M | 60.00M | 0 |
| Revenue growth (YoY) | +3749.17% | +99.03% | -95.64% | +0.79% | +33.09% | -88.89% | +184.40% | — | — | — | — | — |
| Operating Expenses | 54.71M | 60.02M | 57.79M | 51.13M | 47.59M | 47.63M | 43.86M | 46.13M | 42.96M | 48.64M | 36.95M | 38.33M |
| Research & Development | 42.06M | 46.74M | 46.36M | 40.00M | 37.04M | 35.89M | 34.90M | 35.97M | 33.52M | 33.73M | 28.90M | 30.66M |
| Operating Income | 158.77M | -3.65M | -50.35M | -46.42M | -42.04M | -19.31M | 126.78M | -41.45M | -38.79M | 206.31M | 23.05M | -38.33M |
| Other Income (Expense) | -81.00K | 53.00K | -124.00K | 33.00K | 36.00K | 82.00K | 31.00K | 141.00K | 97.00K | -19.00K | 44.00K | -31.00K |
| Pretax Income | 165.11M | 2.28M | -43.72M | -39.34M | -34.60M | -11.65M | 133.66M | -33.63M | -31.29M | 210.67M | 27.34M | -34.10M |
| Income Tax | 2.27M | -1.50M | 666.00K | 0 | 172.00K | 0 | 1.99M | -420.00K | -676.00K | 3.33M | 0 | 0 |
| Net Income | 162.85M | 3.78M | -44.38M | -39.34M | -34.77M | -11.65M | 131.67M | -33.21M | -30.62M | 207.34M | 27.34M | -34.10M |
| Net Income growth (YoY) | — | — | -133.71% | — | — | -105.62% | +381.70% | — | — | — | — | — |
| EPS (Basic) | 2.47 | 0.06 | -0.69 | -0.62 | -0.55 | -0.19 | 2.10 | -0.54 | -0.50 | 3.41 | 0.54 | -0.58 |
| EPS (Diluted) | 2.29 | 0.05 | -0.69 | -0.62 | -0.55 | -0.19 | 2.01 | -0.54 | -0.50 | 3.26 | 0.54 | -0.58 |
| Shares Outstanding (Basic) | 65.94M | 65.09M | — | 63.77M | 63.51M | 62.96M | — | 61.77M | 61.31M | 60.86M | — | 59.18M |
| Shares Outstanding (Diluted) | 71.01M | 70.49M | — | 63.77M | 63.51M | 62.96M | — | 61.77M | 61.31M | 63.60M | — | 59.18M |
| EBITDA | 159.16M | -3.24M | -49.98M | -46.06M | -41.74M | -19.07M | 126.90M | -41.22M | -38.55M | 206.54M | 23.30M | -38.08M |
| Operating Margin | 74.37% | -6.47% | -677.09% | -985.17% | -758.04% | -68.18% | 74.30% | -886.70% | -930.96% | 80.92% | 38.42% | — |
| Net Margin | 76.28% | 6.71% | -596.80% | -834.87% | -626.96% | -41.15% | 77.17% | -710.37% | -734.73% | 81.32% | 45.56% | — |
This table shows 12 quarterly periods of Protagonist Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow PTGX's reporting calendar. What is a income statement?